BiotechTube

Crovalimab

Phase 3Active
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atypical Hemolytic Uremic Syndrome

Conditions

Atypical Hemolytic Uremic Syndrome

Trial Timeline

Oct 22, 2021 → Aug 20, 2029

NCT ID
NCT04861259

About Crovalimab

Crovalimab is a phase 3 stage product being developed by Chugai Pharmaceutical for Atypical Hemolytic Uremic Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT04861259. Target conditions include Atypical Hemolytic Uremic Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT04958265Phase 3Active
NCT04861259Phase 3Active

Competing Products

18 competing products in Atypical Hemolytic Uremic Syndrome

See all competitors
ProductCompanyStageHype Score
CrovalimabChugai PharmaceuticalPhase 3
77
DuloxetineEli LillyApproved
85
Teriparatide 20 mcgEli LillyPhase 3
77
BaricitinibEli LillyPre-clinical
23
RavulizumabAstraZenecaPre-clinical
23
EculizumabAstraZenecaPhase 3
77
IptacopanNovartisPhase 3
77
Iptcaopan 200 mgNovartisPhase 3
77
IptacopanNovartisPhase 3
77
Ropeginterferon Alfa-2BPharmaEssentiaPhase 2
51
CCX168AmgenPhase 2
51
Tazemetostat + Nivolumab + IpilimumabBristol Myers SquibbPhase 1/2
40
CemdisiranAlnylam PharmaceuticalsPhase 2
49
cemdisiran + PlacebosAlnylam PharmaceuticalsPhase 2
49
Axatilimab + AzacitidineIncytePhase 1/2
38
Gemcitabine + PaxalisibPacific BiosciencesPhase 2
44
Apatinib MesylateBrain BiotechPre-clinical
15
azurin-derived cell-penetrating peptide p28Brain BiotechPhase 1
25

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77